{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":16,"sponsored":0,"items":[{"id":"n_6vd2fiubnm3naa3tfjwq","seq":1473690,"kind":"article","title":"Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories","url":"https://www.insidermonkey.com/news/eli-lilly-lly-and-abbvie-abbv-are-expanding-their-pipelines-their-valuations-tell-two-different-stories-1847639","published":"2026-10-03T04:19:17Z","seen":"2026-10-03T04:19:17Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","health","business"],"authors":["Faheem Tahir"],"entities":[{"id":"Q2984214","name":"Eli Lilly","type":"org"},{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_6vd2fiubnm3naa3tfjwq","category":"economy-business","category_p":0.93,"sentiment":"neutral","tone":0.08,"political":0.01},{"id":"n_a7tzjfvsj65imkfw5qxq","seq":1450532,"kind":"article","title":"CX Institutional Cuts Stock Position in AbbVie Inc. $ABBV","url":"https://www.dailypolitical.com/2026/10/02/cx-institutional-cuts-stock-position-in-abbvie-inc-abbv.html","published":"2026-10-02T23:54:49Z","seen":"2026-10-02T23:54:49Z","lang":"en","source":{"id":"dailypolitical.com","name":"dailypolitical.com","domain":"dailypolitical.com"},"via":"gdelt-gkg-english","topics":["economy","disaster","business","politics"],"authors":["Tyrone Williams"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_a7tzjfvsj65imkfw5qxq","category":"economy-business","category_p":0.69,"sentiment":"neutral","tone":0.19,"political":0.09},{"id":"n_6zx45wsodxlvt3e7mivq","seq":1450374,"kind":"article","title":"AbbVie Inc. $ABBV Shares Sold by CX Institutional","url":"https://www.tickerreport.com/banking-finance/13607311/abbvie-inc-abbv-shares-sold-by-cx-institutional.html","published":"2026-10-02T23:54:49Z","seen":"2026-10-02T23:54:49Z","lang":"en","source":{"id":"tickerreport.com","name":"tickerreport.com","domain":"tickerreport.com"},"via":"gdelt-gkg-english","topics":["economy","business","politics","health"],"authors":["Shane Hupp"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_a7tzjfvsj65imkfw5qxq","category":"economy-business","category_p":0.82,"sentiment":"neutral","tone":0.2,"political":0.03},{"id":"n_lgg5zweve5cdmpky6cyq","seq":964572,"kind":"article","title":"AbbVie Stock: Buy, Sell, or Hold in October?","url":"https://www.aol.com/articles/abbvie-stock-buy-sell-hold-165000000.html","published":"2026-09-30T16:50:00Z","seen":"2026-09-30T17:25:39Z","lang":"en","source":{"id":"aol.com","name":"aol.com","domain":"aol.com","outlet":{"wikidata":"Q27585","name":"AOL","type":"website","country":"US","designations":["business","company","enterprise","media company","online service provider","search engine","web portal"]}},"via":"gdelt-gkg-english","topics":["economy","business"],"authors":["AOL"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_vvdgjl4bf675lkrehqla","category":"economy-business","category_p":0.88,"sentiment":"neutral","tone":0.18,"political":0.0},{"id":"n_u4eib6sbq2gp7hicojda","seq":934205,"kind":"article","title":"AbbVie To Present New Dermatology Data At 2026 EADV Congress","url":"https://www.finanzen.ch/nachrichten/aktien/abbvie-to-present-new-dermatology-data-at-2026-eadv-congress-1036586047","published":"2026-09-30T14:55:43Z","seen":"2026-09-30T14:55:43Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","politics","health"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_zyrk7wkz2kpx42bbvqiq","category":"health","category_p":0.37,"category2":"economy-business","sentiment":"neutral","tone":-0.25,"political":0.06},{"id":"n_4lud7b4vkbavvxd726rq","seq":900383,"kind":"article","title":"BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength","url":"https://247wallst.com/investing/2026/09/30/bofa-boosts-abbvie-and-jj-price-targets-on-growth-and-pipeline-strength","published":"2026-09-30T11:15:00Z","seen":"2026-09-30T12:27:07Z","lang":"en","source":{"id":"247wallst.com","name":"247wallst.com","domain":"247wallst.com","outlet":{"wikidata":"Q68896999","name":"24/7 Wall St.","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["disaster","economy","business","health"],"authors":["Vandita Jadeja"],"entities":[{"id":"Q487907","name":"Bank of America","type":"org"},{"id":"Q14662364","name":"AbbVie","type":"org"},{"id":"Q333718","name":"Johnson & Johnson","type":"org"}],"story":"st_ppzo2lsrgkclvilb2djq","category":"economy-business","category_p":0.98,"sentiment":"positive","tone":0.42,"political":0.05},{"id":"n_oypydhahltys5cmubzvq","seq":876584,"kind":"article","title":"AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026","url":"http://www.prnewswire.com/news-releases/abbvie-presents-detailed-phase-1-data-for-abbv-295-a-long-acting-amylin-analog-demonstrating-favorable-tolerability-and-pharmacokinetic-profile-at-easd-2026-302893611.html","published":"2026-09-30T10:08:22Z","seen":"2026-09-30T10:08:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["health","business","economy","politics"],"authors":["AbbVie"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_oypydhahltys5cmubzvq","category":"science-technology","category_p":0.39,"category2":"health","sentiment":"neutral","tone":-0.05,"political":0.07},{"id":"n_3nhac62pw3z6rtkdsuha","seq":844311,"kind":"article","title":"AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026","url":"http://www.prnewswire.com/news-releases/abbvie-highlights-positive-results-from-the-phase-2-apex-part-b-study-of-zumilokibart-in-moderate-to-severe-atopic-dermatitis-as-a-late-breaker-at-eadv-2026-302893602.html","published":"2026-09-30T07:14:32Z","seen":"2026-09-30T07:14:32Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","business","politics","health"],"authors":["AbbVie"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_3nhac62pw3z6rtkdsuha","category":"health","category_p":0.35,"category2":"economy-business","sentiment":"positive","tone":0.05,"political":0.07},{"id":"n_fyhjb2vilvonurft4n6q","seq":832149,"kind":"article","title":"AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress","url":"http://www.prnewswire.com/news-releases/abbvie-showcases-leadership-in-dermatology-research-with-new-clinical-and-real-world-evidence-across-immune-mediated-skin-diseases-at-2026-eadv-congress-302891825.html","published":"2026-09-30T05:40:22Z","seen":"2026-09-30T05:40:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics","science"],"authors":["AbbVie"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_fyhjb2vilvonurft4n6q","category":"health","category_p":0.45,"sentiment":"neutral","tone":-0.23,"political":0.07},{"id":"n_fs6d2ikjihfxnwawjuda","seq":513842,"kind":"article","title":"Can AbbVie's Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?","url":"https://www.insidermonkey.com/news/can-abbvies-backing-help-adarx-win-over-biotech-ipo-investors-at-a-1-74-billion-valuation-1845898","published":"2026-09-28T20:08:19Z","seen":"2026-09-28T20:08:19Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Noor Ul Ain Rehman"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_fs6d2ikjihfxnwawjuda","category":"economy-business","category_p":0.89,"sentiment":"positive","tone":0.34,"political":0.09},{"id":"n_zczvruntcdmcuk7ulaxq","seq":502718,"kind":"article","title":"AbbVie Wins FDA Approval For JUVMO In Parkinson's Disease","url":"https://www.rttnews.com/3694422/abbvie-wins-fda-approval-for-juvmo-in-parkinson-s-disease.aspx","published":"2026-09-28T16:18:00Z","seen":"2026-09-28T19:13:29Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","disaster"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_nrtzh5trtvy4yjwe6paq","category":"health","category_p":0.69,"sentiment":"positive","tone":-0.18,"political":0.03},{"id":"n_4qqteke4jwluxpc4zara","seq":446151,"kind":"article","title":"AbbVie quer incluir comprimido para doença de Crohn no SUS","title_en":"AbbVie wants to include a Crohn's disease pill in the public health system","url":"https://valor.globo.com/empresas/noticia/2026/09/28/abbvie-quer-incluir-comprimido-para-doena-de-crohn-no-sus.ghtml","summary":"O laboratório americano Abbvie quer ampliar a indicação do upadacitinibe no Sistema Único de Saúde (SUS). O medicamento, cujo nome comercial é Rinvoq, já é coberto pela rede pública para artrite reumatoide e, em breve, dermatite atópica em adolescentes, mas o laboratório quer estender a indicação para doença de Crohn e outros dois tipos de inflamação que já contam com aprovação da Anvisa, a agência reguladora brasileira. Matéria exclusiva para assinantes. Para ter acesso…","published":"2026-09-28T14:01:00Z","seen":"2026-09-28T14:21:03Z","lang":"pt","country":"BR","source":{"id":"kite-pox-globo-com-4344ca","name":"pox.globo.com","domain":"pox.globo.com"},"via":"kite-pox-globo-com-4344ca","topics":["valor"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"image":"https://s2-valor.glbimg.com/6owgPXsTLnGD75FeuluyxJqWbP8=/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2026/8/q/7rPnxBQnmbsToAUoC0YQ/170926flavio12.jpg","story":"st_4qqteke4jwluxpc4zara","category":"health","category_p":0.86,"sentiment":"neutral","tone":0.02,"political":0.16},{"id":"n_3l7hzfbmw4xnqkacvutq","seq":442570,"kind":"article","title":"STAT+: AbbVie wins FDA nod for Parkinson’s pill","url":"https://www.statnews.com/2026/09/28/biotech-news-abbvie-wins-fda-nod-for-parkinsons-pill","summary":"The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.","published":"2026-09-28T13:40:32Z","seen":"2026-09-28T13:53:49Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-aa5345","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-aa5345","topics":["healthcare","usa","medicine","biotech","business","pharma","the readout","abbvie"],"authors":["Meghana Keshavan"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"image":"https://www.statnews.com/wp-content/uploads/2024/07/AdobeStock_428671491_Editorial_Use_Only-645x645.jpeg","mentions":3,"story":"st_3l7hzfbmw4xnqkacvutq","category":"health","category_p":0.59,"category2":"economy-business","sentiment":"positive","tone":0.53,"political":0.05},{"id":"n_nrtzh5trtvy4yjwe6paq","seq":451213,"kind":"article","title":"AbbVie Announces FDA Approval Of JUVMO For Parkinson's Disease","url":"https://www.rttnews.com/3694344/abbvie-announces-fda-approval-of-juvmo-for-parkinson-s-disease.aspx","published":"2026-09-28T12:18:00Z","seen":"2026-09-28T14:41:23Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health","business"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q11085","name":"Parkinson's disease","type":"event"}],"story":"st_nrtzh5trtvy4yjwe6paq","category":"health","category_p":0.66,"sentiment":"positive","tone":0.28,"political":0.05},{"id":"n_dqtmtxsrc6i3qbtvctla","seq":403808,"kind":"article","title":"AbbVie's Once-Daily Parkinson's Pill Juvmo Wins FDA Approval, with Nausea, Dizziness, and Headache Common in Trials","url":"https://www.medicaldaily.com/juvmo-tavapadon-fda-approval-parkinsons-side-effects-479174","summary":"The FDA approved Juvmo (tavapadon), AbbVie's once-daily Parkinson's pill. Here's how it works, which side effects trials found, and what to ask.","published":"2026-09-28T10:15:21Z","seen":"2026-09-28T10:47:54Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"mentions":2,"story":"st_dqtmtxsrc6i3qbtvctla","category":"health","category_p":0.75,"sentiment":"neutral","tone":0.15,"political":0.04},{"id":"n_f635ga5ev372ducpxssa","seq":311939,"kind":"article","title":"애브비 파킨슨병 신약 '주브모' 美 승인…초기·진행 환자 모두 겨냥","title_en":"AbbVie Parkinson's disease drug 'Zuvmo' approved in the US... targeting both early and advanced patients","url":"https://www.medipana.com/news/articleView.html?idxno=418295","summary":"애브비의 경구용 파킨슨병 치료제 \\'주브모(Juvmo·성분명 타바파돈)\\'가 미국 식품의약국(FDA) 승인을 받았다. 초기 환자에게 단독으로 투여한 임상과 기존 레보도파 치료 중 증상 변동을 겪는 환자에게 추가 투여한 임상에서 모두 효과를 확인한 신약이다. FDA는 지난 25일(현지시간) 주브모를 성인 파킨슨병 치료제로 승인했다. 주브모는 하루 한 번 복용하며, 도파민 D1·D5 수용체에 선택적으로 작용하는 부분작용제다. FDA의 공개 승인 목록은 성인 파킨슨병이라는 적응증을 명시하고 있다. 허가 신청의 근거가 된 3상 \\'TEMPO\\'","published":"2026-09-27T22:30:38Z","seen":"2026-09-27T23:21:41Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q14662364","name":"AbbVie","type":"org"}],"story":"st_f635ga5ev372ducpxssa","category":"health","category_p":0.78,"sentiment":"positive","tone":0.35,"political":0.12}]}